title: Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma.
authors.forename: E
authors.initials: E
authors.lastname: Raymond
authors.forename: A
authors.initials: A
authors.lastname: de Gramont
authors.forename: C
authors.initials: C
authors.lastname: Louvet
authors.forename: C
authors.initials: C
authors.lastname: Tournigand
authors.forename: B
authors.initials: B
authors.lastname: Demuynck
authors.forename: K
authors.initials: K
authors.lastname: Beerblock
authors.forename: E
authors.initials: E
authors.lastname: Carola
authors.forename: M
authors.initials: M
authors.lastname: Krulik
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
chemical_list: D002945:Cisplatin; D005472:Fluorouracil; D006918:Hydroxyurea